This requires Flash to play. Click here to download.

The information on this site is intended for health care professionals
in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety profile Dosage Reimbursement Resource center CTCL overview Prescribing Information Patient Information
Patient Product Information

Types of CTCL

Indolent CTCLs

  • Mycosis fungoides
  • MF variants and subtypes
  • Folliculotropic MF
  • Pagetoid reticulosis
  • Granulomatous slack skin
  • Subcutaneous panniculitislike T-cell lymphoma
  • CD4+ small/medium pleomorphic T-cell lymphoma
  • CD30+ lymphoproliferative disorders
  • Anaplastic large cell lymphoma
  • Lymphomatoid papulosis

Aggressive CTCLs

  • Sézary syndrome
  • Cutaneous peripheral T-cell lymphoma, unspecified
  • Cutaneous aggressive CD8+ T-cell lymphoma
  • Cutaneous γ/δ T-cell lymphoma
  • Cutaneous NK/T-cell lymphoma, nasal type
Reference: 1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.

Home | Patient Information | Prescribing Information
ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

20951007(3)-05/09-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.